Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Please provide your email address to receive an email when new articles are posted on . Patients with melanoma who have a decrease in ctDNA 3 to 4 weeks after immunotherapy had improved outcomes.

Researchers at UCLA have found a way to supercharge immune cells with a fuel source that tumors can't steal, dramatically ...

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

In an interview with CURE, Dr. Susana Campos, clinical director of the Division of Gynecologic Oncology and assistant professor of medicine at Harvard Medical School, discussed re ...

Cancer immunotherapy has transformed oncology, yet many patients fail to respond or eventually develop resistance.

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.

Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses.

The gut microbiome has been shown to influence tumor growth and contribute to therapeutic resistance. Scientists have concluded that there are both beneficial and deleterious microbes within the gut ...